PFIZER INC
PFIZER INC (PFE): 111 pipeline candidates · 20 upcoming catalysts · ~12 mo cash runway · 121 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
11.8 months
D/E 1.30
Lead: Approved
111 candidates
20 upcoming, next in ~93d
N/A
A transparent, data-derived signal for PFIZER INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$147.7B
Cash
$1.8B
Quarterly Burn
$5.5B
Runway
11.8 mo
Revenue
$14.5B
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (111 candidates)
| Drug | Phase |
|---|---|
| [oxoisoindolin-14c]arv-471 | Phase 1 |
| [phenyl-14c]arv-471 | Phase 1 |
| 5-fu | Phase 3 |
| abiraterone | Phase 4 |
| abrilada | Approved |
| abrilada | Approved |
| ARV-471 | Phase 1 |
| brentuximab vedotin | Phase 2 |
| candidate 1 | Phase 2 |
| candidate 2 | Phase 2 |
Showing 10 of 111 candidates. Sign up for full pipeline.
Upcoming Catalysts (20)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2,932
Total value held
$114.06B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 738,860,024 | $20.75B |
| blackrock, inc. | 498,257,550 | $13.99B |
| state street corp | 301,589,865 | $8.47B |
| geode capital management, llc | 133,561,742 | $3.74B |
| vanguard portfolio management llc | 116,734,695 | $3.28B |
| morgan stanley | 92,685,370 | $2.60B |
| northern trust corp | 62,026,552 | $1.74B |
| massachusetts financial services co /ma/ | 56,911,830 | $1.62B |
| state farm mutual automobile insurance co | 54,508,560 | $1.53B |
| bank of new york mellon corp | 53,879,900 | $1.51B |
Showing top 10 of 2,932 institutional holders of PFIZER INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in PFIZER INC's pipeline?
PFIZER INC (PFE) has 111 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PFIZER INC's lead drug candidate?
PFIZER INC's most advanced tracked candidate is [oxoisoindolin-14c]arv-471 (Phase 1) for Healthy.
What is PFIZER INC's next catalyst?
PFIZER INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monot" — expected September 19, 2026.
What is PFIZER INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PFIZER INC has approximately 11.8 months of cash runway.
What is PFIZER INC's market capitalization?
PFIZER INC's market capitalization is approximately $147.7B.
Get the full picture on PFIZER INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.